To Evaluate HU-045 With Moderate to Severe Glabellar Lines

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines
Epistemonikos ID: 05c38226d0df3d009beaed32c9471d715db8cd7e
First added on: Oct 14, 2026